Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. AMIX
AMIX logo

AMIX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Autonomix Medical Inc (AMIX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.360
1 Day change
-6.43%
52 Week Range
2.640
Analysis Updated At
2026/06/18
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Autonomix Medical Inc (AMIX) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock exhibits bearish technical indicators, lacks positive trading signals, and has no significant catalysts to drive immediate growth. While the reverse stock split may enhance market perception, it does not provide a clear long-term growth trajectory. Given the investor's profile, it is better to hold off on investing in AMIX until there is more clarity on its financial performance and growth potential.

Technical Analysis

The technical indicators for AMIX are bearish. The MACD is negatively expanding and below 0, the RSI is at 29.49 (neutral zone), and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with a regular market change of -6.38% and a post-market change of -7.00%.

Positive Catalysts

  • The company is implementing a 1-for-21 reverse stock split to enhance market perception and investor confidence. Shares will resume trading on Nasdaq under the ticker symbol 'AMIX'.

Neutral/Negative Catalysts

  • The stock has experienced significant price declines (-6.38% in regular market and -7.00% in post-market). Technical indicators are bearish, and there is no clear signal of growth or momentum. Hedge funds and insiders are neutral, showing no significant trading trends.

Financial Performance

No financial data available for analysis due to an error.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available for review.

Wall Street analysts forecast AMIX stock price to rise
1 Analyst Rating
Wall Street analysts forecast AMIX stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.389
sliders
Low
5
Averages
5
High
5
Current: 0.389
sliders
Low
5
Averages
5
High
5
Maxim
Maxim
Buy
downgrade
$5 -> $2
AI Analysis
2026-02-17
Reason
Maxim
Maxim
Price Target
$5 -> $2
AI Analysis
2026-02-17
downgrade
Buy
Reason
Maxim lowered the firm's price target on Autonomix to $2 from $5 and keeps a Buy rating on the shares. The company's Q3 results were slightly better than expected, though the firm is cutting its price target on expected share dilution from a likely capital raise, the analyst tells investors in a research note.

People Also Watch